REGULATORY

Chuikyo Raises No Objection to Earlier Price Cuts for LLPs, Payers Want Stricter Rule

June 27, 2019

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

No objection was expressed by members of a key Japanese reimbursement policy panel on June 26 for a proposal to shorten the current price cut timeline for off-patent brand-name drugs if they have authorized generic (AG) versions or high generic…

To read the full story

Chuikyo Supports Earlier Price Cuts for Certain Off-Patent Brand-Name Drugs
September 26, 2019

REGULATORY

Japan Sets New Pricing Rules for Conditionally Approved Regenerative Medicines, Starting with Elevidys
January 15, 2026
MHLW Orders Label Revisions for Aspirin, CAR-T Therapies, and Other Drugs
January 14, 2026
Japan to Stick with 7 New Drug Approval Rounds a Year
January 14, 2026
MHLW to Set Up Expert Panel on Using Disease Registries in Drug Development
January 13, 2026
Chuikyo Moves to Allow Special Mixed-Billing for Santen’s Myopia Drug
January 13, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Gist of FY2026 Drug Pricing Reform Outline

The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…

COMMENTARY

Wave of “World Firsts” Looms as 47 New Drug Candidates Line Up for 2026

By Shinya Sato

As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…

COLUMN

AI: Your New HR BFF (Not Your Replacement!)

By Philip Carrigan

Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…